Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662146 | 0.93 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL562802 | 0.92 | LMNA (0.39) | LMNACA12CA1CA2CA3 | |
| SCHEMBL661961 | 0.91 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL662775 | 0.85 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL661944 | 0.84 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| SCHEMBL660472 | 0.81 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL660732 | 0.78 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL662173 | 0.77 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL659722 | 0.77 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL661439 | 0.75 | LMNA (0.44) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258704-A1 | 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | MICHEL PHILIPPE | 2006-11-16 | — | — | US | claimed |
| US-20040132717-A1 | 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | UCB, S.A. (BE) | 2004-07-08 | — | — | US | claimed |
| EP-1395560-A1 | 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS | UCB, S.A. (BE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002094787-A1 | 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS | UCB, S.A. (BE) | 2002-11-28 | — | — | WO | claimed |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2022-07-14 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| EP-3827820-A1 | BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20100099735-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-04-22 | — | — | US | disclosed |
| WO-2010044878-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7473697-B2 | 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | UCB S.A. (BE) | 2009-01-06 | — | — | US | disclosed |
| US-20060258704-A1 | 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | MICHEL PHILIPPE | 2006-11-16 | — | — | US | disclosed |
| US-7087596-B2 | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | UCB, S.A. (BE) | 2006-08-08 | — | — | US | disclosed |
| US-20040132717-A1 | 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | UCB, S.A. (BE) | 2004-07-08 | — | — | US | disclosed |
| EP-1395560-A1 | 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS | UCB, S.A. (BE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094787-A1 | 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS | UCB, S.A. (BE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132717-A1 | 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | GABRA6, GABRA2, HCAR2 | LMNA 2596/4885CA12 2989/4885CA1 723/4885 |
| US-20060258704-A1 | 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders | GABRA6, HCAR2, GABRA2 | LMNA 2587/4885CA12 2982/4885CA1 764/4885 |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | LMNA 1805/4885CA12 302/4885CA1 322/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | LMNA 1020/4885CA12 483/4885CA1 828/4885 |
| US-20100099735-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | LMNA 1805/4885CA12 302/4885CA1 322/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | LMNA 763/4885CA12 825/4885CA1 350/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | LMNA 1152/4885CA12 123/4885CA1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.